ImmuneBridge
immunebridge.com
Actively hiring
LLM & Generative AI
Artificial Intelligence
Biotechnology
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$15.8M
2 rounds on record
Latest round
$5.6M
Venture round · Mar 2025 · 18 mo ago
Team
7
US Form 5500 (plan participants) · Dec 2025 · -13% in a year
Backers
1
M Ventures
The money's age
Due for its next round
18 months since the last round · not hiring
Momentum
0/100
no fresh signals
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Mar 2025 | $5.6M | — | SEC Form D |
| Venture round | Dec 2022 | $10.2M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | ImmuneBridge Inc. | sec |
Founders and leadersfrom filings, registers and the company's site
Peretz PartenskyExecutive Officer, DirectorSEC Form D
Stuart JacobsonExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
M Ventures Overview
Building the next generation of cell therapies. Cell therapies face key challenges that limit their efficacy and accessibility:.
People
Peretz Partensky
Executive Officer, Director
Stuart Jacobson
Executive Officer, Director
Alicia Jackson
Director
Cheryl Zimberlin
Director
Gregory Bonfiglio
Director
Dylan Morris
Director
Mary Warren
Director
Nadiya Ishnazarova
Director
Omri Amirav-Drory
Director
Thomas Farrell
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Francisco
United States
HQ
Contact Us
50-200 est. staff
2122 Bryant St, San Francisco, CA 94110